Reliable biomarkers for frontotemporal dementia (FTD) are required for accurate discrimination between dementia types, prediction of clinical progression and tailoring of pharmacological interventions. This Review discusses the increasing number of available biomarkers for FTD — including novel imaging modalities and fluid biomarkers — and the future challenges in their implementation.
- Lieke H. Meeter
- Laura Donker Kaat
- John C. van Swieten